PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
26550923-9	2015	In period 2, fewer infants received antibiotics after the third day of life (43 vs. 66%, p=0.04), systemic glucocorticoids were less frequently used (7.5 vs. 23%, p=0.04), and more infants received doxapram (34 vs. 2.3%, p<0.0001).	Doxapram	198-206	period circadian regulator 2	Homo sapiens	3-11
25248340-3	2015	Estimates generated by NONMEM indicated that clearance of doxapram (CL; L/kg/h) was affected by postmenstrual age (PMA; weeks), body weight (BW; g), and aspartate aminotransferase (AST; IU/L).	Doxapram	58-66	solute carrier family 17 member 5	Homo sapiens	153-179
25248340-3	2015	Estimates generated by NONMEM indicated that clearance of doxapram (CL; L/kg/h) was affected by postmenstrual age (PMA; weeks), body weight (BW; g), and aspartate aminotransferase (AST; IU/L).	Doxapram	58-66	solute carrier family 17 member 5	Homo sapiens	181-184
25248340-8	2015	We found that doxapram was metabolized by CYP3A4/5.	Doxapram	14-22	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	42-48
20140700-6	2010	When the methionine sulfoximine (MS, 10 microM), a blockage of glutamine synthetase, was applied, all the exciting effects of doxapram on RRDA were reversed.	Doxapram	126-134	glutamate-ammonia ligase	Rattus norvegicus	63-83
24527224-2	2014	Doxapram hydrochloride is a respiratory stimulant that has an inhibitory effect on myocardial IK1 potassium channels and is thought to increase membrane instability and excitability in myocardial cells.	Doxapram	0-22	potassium calcium-activated channel subfamily N member 4	Rattus norvegicus	94-97
23448699-7	2013	Doxapram treated infants were more likely to receive caffeine, furosemide, insulin and mechanical ventilation.	Doxapram	0-8	insulin	Homo sapiens	75-82
23448699-11	2013	Cox model"s multivariate analysis showed that administration of furosemide and doxapram significantly increased the occurrence of severe hypokalaemia with relative risks of 4.9 (95% CI 1.9 to 12.5) and 8.2 (95% CI 3.1 to 21.7), respectively.	Doxapram	79-87	cytochrome c oxidase subunit 8A	Homo sapiens	0-3
16845643-6	2007	ACTH and cortisol levels were higher in a challenge paradigm (doxapram) than in a resting state study, and paradigm-related ACTH secretion was exaggerated in patients with panic disorder.	Doxapram	62-70	proopiomelanocortin	Homo sapiens	0-4
1855351-3	1991	The concentrations of doxapram and its metabolites (AHR 0914, an analog of doxapram, AHR 5955 or ketodoxapram, and AHR 5904) were measured by high pressure liquid chromatography.	Doxapram	22-30	aryl hydrocarbon receptor	Homo sapiens	52-55
12742673-0	2003	Rodent doxapram model of panic: behavioral effects and c-Fos immunoreactivity in the amygdala.	Doxapram	7-15	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	55-60
12742673-6	2003	The effect of doxapram on c-Fos-like immunoreactivity was examined in three brain regions.	Doxapram	14-22	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	26-31
12742673-9	2003	Doxapram induced c-Fos-like immunoreactivity in the central nucleus of the amygdala but not the lateral nucleus or the nucleus tractus solitarius.	Doxapram	0-8	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	17-22
1957596-0	1991	Low-dose doxapram therapy in premature infants and its CSF and serum concentrations.	Doxapram	9-17	colony stimulating factor 2	Homo sapiens	55-58
1855351-7	1991	The oxidative pathway producing keto-doxapram, or AHR 5955 and AHR 5904, is more active than the de-ethylation producing the analog of doxapram AHR 0914.	Doxapram	37-45	aryl hydrocarbon receptor	Homo sapiens	50-53
1855351-7	1991	The oxidative pathway producing keto-doxapram, or AHR 5955 and AHR 5904, is more active than the de-ethylation producing the analog of doxapram AHR 0914.	Doxapram	37-45	aryl hydrocarbon receptor	Homo sapiens	63-66
1855351-7	1991	The oxidative pathway producing keto-doxapram, or AHR 5955 and AHR 5904, is more active than the de-ethylation producing the analog of doxapram AHR 0914.	Doxapram	37-45	aryl hydrocarbon receptor	Homo sapiens	63-66
17190148-2	2006	METHODS: With the doxapram as internal standard, Oasis column was used to extract drugs from whole blood and the sample was analysized by CZE.	Doxapram	18-26	cAMP responsive element binding protein 3 like 1	Homo sapiens	49-54
16269353-0	2005	Doxapram increases corticotropin-releasing factor immunoreactivity and mRNA expression in the rat central nucleus of the amygdala.	Doxapram	0-8	corticotropin releasing hormone	Rattus norvegicus	19-49
16269353-3	2005	Doxapram injection significantly increased CRF-like immunoreactivity (CRF-IR) within the CeA, but not in the BNST or PVN, and this increase was significant 2h after injection.	Doxapram	0-8	carcinoembryonic antigen gene family 4	Rattus norvegicus	89-92
16269353-4	2005	In addition, doxapram significantly increased CRF mRNA expression within the CeA, and this was most prominent 30min after injection.	Doxapram	13-21	carcinoembryonic antigen gene family 4	Rattus norvegicus	77-80
16269353-5	2005	These results suggest that doxapram selectively increases CRF expression within the CeA, and that this is mediated by increased CRF gene transcription.	Doxapram	27-35	carcinoembryonic antigen gene family 4	Rattus norvegicus	84-87
16269353-6	2005	This increase in CRF-IR within the CeA might explain the doxapram-induced anxiety reaction.	Doxapram	57-65	carcinoembryonic antigen gene family 4	Rattus norvegicus	35-38
8908229-9	1996	Hypoxia affected a moderate increase in PVR in group TIVA (P < 0.05), which was slightly lower at the lowest and highest plasma levels of doxapram (P < 0.05).	Doxapram	141-149	PVR cell adhesion molecule	Sus scrofa	40-43
8908229-10	1996	In group Hal, the induction of hypoxia induced a more pronounced rise in PVR (P < 0.05) which showed a biphasic response to increasing dose levels of doxapram, the lowest dose affecting a further rise (P < 0.05) and the highest a reduction to values below hypoxia control levels (P < 0.05).	Doxapram	153-161	PVR cell adhesion molecule	Sus scrofa	73-76
2052744-0	1991	Induction of hepatic cytochrome P-450 and drug metabolism by doxapram in the mouse.	Doxapram	61-69	cytochrome P450, family 21, subfamily a, polypeptide 1	Mus musculus	21-37
2052744-3	1991	Compared with the control values, the doxapram treatment significantly increased the amount of cytochrome P-450, and activities of aminopyrine N-demethylase, ethylmorphine N-demethylase and meperidine N-demethylase.	Doxapram	38-46	cytochrome P450, family 21, subfamily a, polypeptide 1	Mus musculus	95-111
33136614-4	2021	Therefore, in this study, we evaluated the effects of doxapram in Fos (c-Fos) protein expression in the PAG and characterized its cardiorespiratory and behavioral effects on the elevated T maze and in the conditioned place aversion (CPA) paradigms.	Doxapram	54-62	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	66-69
2751921-3	1989	The activity of the acetylcholinesterase in rat diaphragm has been examined also in the presence of doxapram.	Doxapram	100-108	acetylcholinesterase	Rattus norvegicus	20-40
33136614-4	2021	Therefore, in this study, we evaluated the effects of doxapram in Fos (c-Fos) protein expression in the PAG and characterized its cardiorespiratory and behavioral effects on the elevated T maze and in the conditioned place aversion (CPA) paradigms.	Doxapram	54-62	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	71-76
33136614-5	2021	Doxapram increased Fos expression in different columns of the PAG, increased respiratory frequency, decreased heart rate, and increased arterial pressure when injected via intravenous route.	Doxapram	0-8	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	19-22
33210449-11	2021	After doxapram administration, Creatinine (T3), Albumin (T2) and Protein (T2 & T3) decreased while Glucose (T2 & T3) and BT (T3) increased.	Doxapram	6-14	albumin	Canis lupus familiaris	48-55